Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Genitourinary Malignancies
share announcement

Genitourinary Malignancies

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 10044

Special Issue Editor

Dr. Dominick Bosse

E-Mail Website
Guest Editor
Department of Family Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada
Interests: chemotherapy; medical oncology; renal cell carcinoma; prostate cancer; transitional cell carcinoma; germ cell tumors; hepatocellular carcinoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Genitourinary malignancies, including prostate, bladder, kidney, and testicular cancers, are at the forefront of innovation, with a continuous influx of novel therapeutics reshaping treatment paradigms. Although the pipeline of new therapeutics continues to evolve, achieving the ultimate goal of personalized medicine proves challenging. The scarcity of reliable biomarkers predicting responses or toxicities to cancer treatments has prompted the development of several drug combinations which ultimately improve outcomes. Nevertheless, the introduction of these combinations, coupled with numerous recent changes in frontline treatments, has intensified the complexity of treatment selection and sequencing, as well as the optimization of toxicity management and quality of life.

This Special Issue welcomes manuscripts addressing the unknowns surrounding treatment optimization, the development of predictive markers, the refinement of therapy sequencing, and the strategies to improve and prevent drug toxicity as well as patients’ quality of life.

Dr. Dominick Bosse
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genitourinary malignancy
  • renal cell carcinoma
  • prostate cancer
  • urothelial cancer
  • germ cell tumor
  • outcomes
  • toxicities
  • quality of life
  • markers
  • treatment sequencing

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 1254 KiB  
Article
Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients
by Noa Shani Shrem, Ana-Alicia Beltran-Bless, Sunita Ghosh, Camilla Tajzler, Lori A. Wood, Christian Kollmannsberger, Naveen S. Basappa, Jeffrey Graham, Nazanin Fallah-Rad, Daniel Y.C. Heng, Denis Soulières, Aly-Khan A. Lalani, Rodney H. Breau, Antonio Finelli, Simon Tanguay, Bimal Bhindi, Georg Bjarnason, Frederic Pouliot and Christina Canil
Cancers 2025, 17(3), 522; https://doi.org/10.3390/cancers17030522 - 4 Feb 2025
Viewed by 1240
Abstract
Background: Ipilimumab and nivolumab (ipi/nivo) improved overall survival (OS) compared to sunitinib in the pivotal Checkmate 214 trial of metastatic renal cell carcinoma (mRCC) with International Metastatic RCC Database Consortium (IMDC) intermediate/poor risk disease. We evaluated the efficacy and toxicity of ipi/nivo in [...] Read more.
Background: Ipilimumab and nivolumab (ipi/nivo) improved overall survival (OS) compared to sunitinib in the pivotal Checkmate 214 trial of metastatic renal cell carcinoma (mRCC) with International Metastatic RCC Database Consortium (IMDC) intermediate/poor risk disease. We evaluated the efficacy and toxicity of ipi/nivo in older and frailer populations in a real-world mRCC cohort. Methods: Analysis was conducted on a real-world cohort with mRCC (N = 551) treated with first-line ipi/nivo from the Canadian Kidney Cancer information system (CKCis) database from January 2014 to December 2021. A comparison was made between outcomes and toxicity in patients 1. <70 versus (vs.) ≥70 yo, 2. <75 vs. ≥75 yo, and 3. KPS ≥70 vs. <70 yo. OS, progression-free survival (PFS), and time to treatment failure (TTF) were calculated by Kaplan–Meier analysis. Log-rank tests were used for comparison between groups. Results: Ipi/nivo treatment had no impact on survival outcomes or toxicity for patients >70 yo and >75 yo when controlled for IMDC. However, when comparing patients with KPS > 70 vs. KPS < 70, patients with a poor performance status had decreased median OS at 54.5 m vs. 10.8 m (p-value < 0.0001) and PFS at 11.6 vs. 3.1 m (p-value < 0.0001). Conclusions: The use of ipi/nivo in mRCC demonstrated similar survival outcomes and toxicity in an older patient population. In patients with a poor performance status, it was associated with inferior OS and PFS. We believe that ipi/nivo is a reasonable treatment option for these patient populations, particularly in older patients. Full article
(This article belongs to the Special Issue Genitourinary Malignancies)
►▼ Show Figures

Figure 1

9 pages, 823 KiB  
Article
Magnetic-Resonance-Imaging-Guided Cryoablation for Solitary-Biopsy-Proven Renal Cell Carcinoma: A Tertiary Cancer Center Experience
by Mohamed E. Abdelsalam, Nabeel Mecci, Ahmed Awad, Roland L. Bassett, Bruno C. Odisio, Peiman Habibollahi, Thomas Lu, David Irwin, Jose A. Karam, Surena F. Matin and Kamran Ahrar
Cancers 2024, 16(10), 1815; https://doi.org/10.3390/cancers16101815 - 10 May 2024
Cited by 1 | Viewed by 1624
Abstract
Background: Our purpose is to evaluate the long-term oncologic efficacy and survival rates of MRI-guided cryoablation for patients with biopsy-proven cT1a renal cell carcinoma (RCC). Materials and Methods: We retrospectively reviewed our renal ablation database between January 2007 and June 2021 and only [...] Read more.
Background: Our purpose is to evaluate the long-term oncologic efficacy and survival rates of MRI-guided cryoablation for patients with biopsy-proven cT1a renal cell carcinoma (RCC). Materials and Methods: We retrospectively reviewed our renal ablation database between January 2007 and June 2021 and only included patients with solitary-biopsy-proven cT1a RCC (≤4 cm) who underwent MRI-guided cryoablation. We excluded patients with genetic syndromes, bilateral RCC, recurrent RCC or benign lesions, those without pathologically proven RCC lesions and patients who underwent radiofrequency ablation or CT-guided cryoablation. For each patient, we collected the following: age, sex, lesion size, right- or left-sided, pathology, ablation zone tumor recurrence, development of new tumor in the kidney other than ablation zone, development of metastatic disease, patient alive or not, date and cause of death. We used the Kaplan and Meier product limit estimator to estimate the survival outcomes. Results: Twenty-nine patients (median age 70 years) met our inclusion criteria. Twenty-nine MRI-guided cryoablation procedures were performed for twenty-nine tumor lesions with a median size of 2.2 cm. A Clavien–Dindo grade III complication developed in one patient (3.4%). Clear cell RCC was the most reported histology (n = 19). The median follow up was 4.5 years. No tumor recurrence or metastatic disease developed in any of the patients. Two patients developed new renal lesions separate from the ablation zone. The 5- and 10-year OS were 72% and 55.6%, respectively. The 5- and 10-year DFS were 90.5% and the 5-year and 10-year LRFS, MFS and CSS were all 100%. Conclusions: MRI-guided cryoablation is a safe treatment with a low complication rate. Long-term follow-up data revealed long-standing oncologic control. Full article
(This article belongs to the Special Issue Genitourinary Malignancies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

25 pages, 2512 KiB  
Review
Diagnosis and Management of Skin Toxicities in Systemic Treatment of Genitourinary Cancers
by Deepro Chowdhury, Laura Chin, Roupen Odabashian, Ali Fawaz, Christina Canil, Michael Ong, Mark G. Kirchhof, Martin. Neil Reaume, Ana-Alicia Beltran-Bless, Marie-France Savard, David J. Tsoulis and Dominick Bossé
Cancers 2025, 17(2), 251; https://doi.org/10.3390/cancers17020251 - 14 Jan 2025
Viewed by 1379
Abstract
The landscape of available therapeutic options for treatment of genitourinary (GU) cancers is expanding dramatically. Many of these treatments have distinct, sometimes severe, skin toxicities including morbilliform, bullous, pustular, lichenoid, eczematous, psoriasiform, and palmoplantar eruptions. Pruritus and skin pigmentation changes have also been [...] Read more.
The landscape of available therapeutic options for treatment of genitourinary (GU) cancers is expanding dramatically. Many of these treatments have distinct, sometimes severe, skin toxicities including morbilliform, bullous, pustular, lichenoid, eczematous, psoriasiform, and palmoplantar eruptions. Pruritus and skin pigmentation changes have also been noted. This review aims to synthesize dermatologic events observed with antibody drug conjugates, poly (ADP-ribose) polymerase (PARP) inhibitors, androgen receptor pathway inhibitors, tyrosine kinase inhibitors, immune checkpoint inhibitors, and the combination of these agents used for the treatment of GU cancers. It provides a guide on diagnosis and initial management of these rashes for medical oncologists. Full article
(This article belongs to the Special Issue Genitourinary Malignancies)
►▼ Show Figures

Figure 1

15 pages, 304 KiB  
Review
Gonadal Teratomas: A State-of-the-Art Review in Pathology
by Cecilia Salzillo, Amalia Imparato, Francesco Fortarezza, Sonia Maniglio, Stefano Lucà, Marco La Verde, Gabriella Serio and Andrea Marzullo
Cancers 2024, 16(13), 2412; https://doi.org/10.3390/cancers16132412 - 29 Jun 2024
Cited by 2 | Viewed by 2196
Abstract
Teratomas are neoplasms arising from germ cells and encompass tissues derived from two or more embryonic germ layers, including ectoderm, mesoderm, and endoderm. These tumours typically localize along the midline or in paramedian positions and can manifest as gonadal (20%) or extragonadal (80%) [...] Read more.
Teratomas are neoplasms arising from germ cells and encompass tissues derived from two or more embryonic germ layers, including ectoderm, mesoderm, and endoderm. These tumours typically localize along the midline or in paramedian positions and can manifest as gonadal (20%) or extragonadal (80%) entities. Although gonadal teratomas are uncommon, they represent the predominant type of gonadal tumour in the paediatric population. They comprise approximately 20–25% of all ovarian tumours in females and about 3–5% of all testicular tumours in males. Ovarian teratomas exhibit a higher incidence in early childhood and adolescence, whereas testicular teratomas are more prevalent during the first three months of life and between the ages of 15 and 19. While the majority of paediatric gonadal teratomas are benign, malignant or mixed variants may also arise, necessitating more aggressive therapeutic interventions. Full article
(This article belongs to the Special Issue Genitourinary Malignancies)
14 pages, 557 KiB  
Review
Advancements in First-Line Treatment of Metastatic Bladder Cancer: EV-302 and Checkmate-901 Insights and Future Directions
by Vijay Kumar Srinivasalu and Debbie Robbrecht
Cancers 2024, 16(13), 2398; https://doi.org/10.3390/cancers16132398 - 29 Jun 2024
Cited by 4 | Viewed by 2733
Abstract
Advanced bladder cancer patients have historically failed to achieve prolonged duration of response to conventional chemotherapy and needed better first-line treatment regimens. The approval of nivolumab in combination with gemcitabine and cisplatin and pembrolizumab with antibody–drug conjugate enfortumab vedotin has revolutionized the first-line [...] Read more.
Advanced bladder cancer patients have historically failed to achieve prolonged duration of response to conventional chemotherapy and needed better first-line treatment regimens. The approval of nivolumab in combination with gemcitabine and cisplatin and pembrolizumab with antibody–drug conjugate enfortumab vedotin has revolutionized the first-line treatment of advanced bladder cancer in many countries. In this review, we summarize the intricate differences between the two landmark clinical trials that led to their incorporation into the current standard of care for advanced bladder cancer. We further discuss newer novel treatment options in the second and subsequent lines of treatment on progression, like immunotherapy in combination with other agents, including fibroblast growth factors receptor inhibitors, human epidermal growth factor inhibitors, antibody–drug conjugates, tyrosine kinase inhibitors, and novel antibodies. Finally, we discuss the integration of these novel therapies into current clinical practice amidst the rapidly evolving landscape of advanced bladder cancer treatment, aiming to enhance patient outcomes. Full article
(This article belongs to the Special Issue Genitourinary Malignancies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop